P53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy
Related Experiment Video
Updated: Oct 29, 2026
Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
Published on: September 10, 2017
M Bergqvist1, D Brattström, A Larsson
1Department of Oncology, Akademiska Hospital, University of Uppsala, Sweden.
Background:
In this study we investigated whether the presence of p53 antibodies in sera before of during/after radiation therapy can predict increased survival in patients with non-small cell lung cancer.
Patients And Materials:
Sera from 67 patients with a histopathologically confirmed diagnosis of nonsmall cell lung cancer have been investigated using sandwich ELISA (Dianova, Hamburg, Germany). Sera was collected before or during/after radiation therapy.
Results:
Antibodies were detected in 18 (27%) patients. 46/67 (69%) of the sera had been taken before start of radiation therapy and the presence of p53 antibodies was a statistically significantly good prognostic factor in terms of increased survival (p = 0.025).
Conclusion:
p53 antibodies in sera, before the start of radiation therapy, can predict increased survival after radiation treatment in patients with non-small cell lung cancer.